Our
Pipeline

PULMATRiX is developing transformational inhaled therapies
for patients with pulmonary disease, both rare and common

PRODUCT PIPELINE

INDICATION

2019

2020

PULMAZOLE
Anti-Fungal

INDICATION

Allergic Bronchopulmonary
Aspergillosis (ABPA) in
Patients with Asthma

PUR1800
NSKI

INDICATION

Acute Exacerbations
of COPD (AECOPD)

PUR5700
NSKI

INDICATION

Idiopathic Pulmonary
Fibrosis (IPF)

PulmazolE

Pulmazole is the antifungal itraconazole, engineered
with iSPERSE to overcome issues with oral administration

Itraconazole is available as an oral formulation, Sporanox®, which may negatively impact efficacy due to poor lung exposure and create tolerability and safety issues due to high plasma exposure.1,2

Pipeline ChartPipeline Chart

Pulmazole™ is currently in a Phase 2 trial for
the treatment of ABPA in patients with asthma.

Learn more at clintrials.gov

FAST FACTS:
ABPA and the Unmet Need for Additional Treatment Options

ABPA is an exaggerated
response of the immune
system
to the fungus
Aspergillus in patients with
asthma and cystic fibrosis4

~1.5% of adult patients with asthma suffer from ABPA~1.5% of adult patients with asthma suffer from ABPA

Current standard of care
includes oral steroids
followed by add-on oral
antifungal treatment when
response is inadequate4

~50% of patients with ABPA have inadequate response to steroids alone. ~20% become dependent upon steroids and are at risk for long-term steroid complications

Current antifungals
are hindered by oral
delivery
which may
adversely affect
efficacy and safety9

Pulmazole is the first inhaled antifungal candidate
designed to overcome the limitations of oral antifungals
and also potentially reduce steroid burden.

Learn more about ABPA

PUR1800

PUR1800

PUR1800 is a Narrow Spectrum Kinase Inhibitor (NSKI) engineered with
iSPERSE that is currently being investigated for the treatment of
AECOPD. PUR1800 targets p38 MAP kinases (p38MAPK), Src kinases,
and Syk kinases.10

These kinases play a critical role in chronic
inflammation and airway remodeling in patients with COPD
.11-13

AECOPD Lung Remodeling ProcessAECOPD Lung Remodeling Process

By targeting these kinases,
PUR1800 is designed TO11-13

1. Block steroid resistant inflammation induced by a variety of stimuli including cytokines and free radical stressors such as cigarette smoke

2. Suppress inflammation associated with infection

3. Treat airway remodeling

FAST FACTS:
AECOPD and The Unmet Need for
Additional Treatment Options

There are ~18M moderate-to-severe cases of AECOPD in the US each year withThere are ~18M moderate-to-severe cases of AECOPD in the US each year with
due to infection-induced inflammation,here the standard of care (steroids) has limited efficacydue to infection-induced inflammation,here the standard of care (steroids) has limited efficacy

PUR1800, engineered with iSPERSE™, has the potential to deliver up
to 3 times the effective lung dose when compared to a lactose blend
formulation, improving delivery while reducing the potential for
unwanted side effects.

Learn more about AECOPD

PUR5700

PUR5700

PUR5700 is a second NSKI
in preclinical development

PUR5700 is a second NSKI
in preclinical development


Preclinical data demonstrate the potential of PUR5700 as a therapy for IPF.

EXPANDED ACCESS STATEMENT

PULMATRiX is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. PULMATRiX is currently developing PUR1900 (PulmazoleTM), an investigational product intended for the treatment of allergic bronchopulmonary aspergillosis (ABPA). Currently there is no approved therapy for ABPA, and patients with ABPA are treated with corticosteroids to counter the inflammatory response to the Aspergillus fungus that lives in the lungs of these patients. Some patients with ABPA also receive systemic antifungal therapy, such as itraconazole. Although these therapies are effective in some patients with ABPA, the use of corticosteroids and systemic antifungals is limited by the potential for serious side effects. PUR1900 is a dry powder iSPERSE inhaled formulation of itraconazole.

A crucial step in the development of investigational products is to conduct clinical trials. Therapeutic products being studied in clinical trials have unknown benefits and unknown risks that will not be understood until the clinical trials are complete. If results from the clinical trials are favorable, they will be submitted to FDA and other regulatory bodies for review of the drug’s safety and efficacy in order to seek approval for the product. Obtaining regulatory approval for a new medicine is the best way to bring rapid access to the greatest number of patients who may benefit.

Sometimes patients may be able to access investigational products outside of a clinical trial. In the United States, this is possible through an expanded access program, also referred to as “compassionate use.” Use of the investigational product in an expanded access program is usually separate from the development program for that product, or at best an adjunct to the carefully designed, controlled, and monitored clinical studies conducted to demonstrate safety and efficacy of the product.

It is very important to systematically obtain information about the safety and tolerability of investigational products in a controlled manner. Currently a safety and tolerability study of PUR1900 is being conducted in patients with stable asthma and ABPA. Data on safety and tolerability of PUR1900 in these patients are not yet available. In the absence of these data, PULMATRiX is not accepting expanded access requests at this time. As information from our clinical trials become available, PULMATRiX will reevaluate this policy and publish any changes to this policy if appropriate.

If you have questions about this policy, or would like information about how to enroll in PUR1900 clinical studies, please contact PULMATRiX at info@pulmatrix.com. You can also obtain information about the current study at https://clinicaltrials.gov.

References: 1. Agarwal R, Dhooria S, Singh Sehgal I, et al. A randomized trial of itraconazole versus prednisolone in acute-stage ABPA complicating asthma. CHEST. 2018.doi: 10.1016/ j.chest.2018.01.005. 2. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infec Dis. 2009;49:928-930. 3. Data on file. PULMATRiX: Lexington, MA. 4. Greenberger PA, Bush RK, Demain JG, et al. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2014; 2(6): 703–708. 5. Centers for Disease Control and Prevention. Aspergillosis statistics. Website available at: https://www.cdc.gov/fungal/diseases/ aspergillosis/statistics.html. Accessed September 30, 2019. 6. Agarwal R, Aggarwal AN, Dhooria S, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016;47:385-387. 7. Shah A, Panjabi C. Allergic bronchopulmonary aspergillosis: a perplexing clinical entity. Allergy Asthma Immunol Res. 2016;8(4):282-297. 8. Patterson R, Greenberger PA, Halwig JM, et al. Allergic bronchopulmonary aspergillosis: natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986;146(5)916-918. 9. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infec Dis. 2002;34:563-571. 10. Curran AK, Charron C, Russel P, et al. PUR1800 (RV1162), a novel narrow spectrum kinase inhibitor, but not fluticasone, reduces TNFα-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients. Presented at: ERS International Congress; Paris, FRA: September 2018. 11. Barnes PJ. Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease. Pharmacol Rev. 2016;68:788-815. 12. Geraghty P, Hardigan A, Foronjy RF. Cigarette smoke activated the proto-oncogene c-Src to promote airway inflammation and lung tissue destruction. Am J Respir Cell Mol Biol. 2013;50(3):559-570. 13. Angata T, Ishii T, Motegi T, et al. Loss of siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci. 2013;70(17):3199-3210. 14. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-1138. 15. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636-645.